GSK Looks To Build On Supportive Care Presence With Promacta And Rezonic

Building on the base of its anti-emetic Zofran, GlaxoSmithKline is poised to broaden its leadership in the market for oncology supportive care with near-term offerings for thrombocytopenia and chemotherapy-induced nausea and vomiting

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet